RxDoctor Payments Data

Brian Rowley

Optometrist · Payson, UTNPI 1588771414

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Coopervision Inc. accounts for 67.2% of it on its own, with 16 other manufacturers making up the rest. Among optometrist clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,668in general payments, 2019–2025

Across 196 payments — averaging $74.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$10K
  • Alcon$3K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$413
  • Bausch & Lomb Americas Inc.$396
  • Optos, Inc.$251
  • AbbVie$251
  • plus $828 from 11 others

What the payments were for

  • Speaking & faculty fees$8,56358%
  • Travel & lodging$8566%
  • Food & beverage$5,16635%
  • Entertainment$841%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,668 in reported general payments places this provider in the 95th percentile of 423 optometrist providers in Utah.

See all optometrist providers in Utah

Medicare billing

Part B allowed, 2024
$26,949
Medicare patients
120
Services billed
331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha28$350
Latanoprost21$229

Paid to pharmacies, not to this prescriber.

Other optometrist in Payson

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →